← All trials
NCT04712838
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2021
- Primary completion
- Apr 13, 2021
- Completion date
- Apr 13, 2021
- First posted
- Jan 15, 2021
- Last posted
- Oct 20, 2021
- Enrollment
- 24
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hengrui Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.